Suscribirse

Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography - 29/06/13

Doi : 10.1016/j.ahj.2013.04.001 
Juan Luis Gutiérrez-Chico, MD, PhD, FESC, FACC a, Lorenz Räber, MD b, Evelyn Regar, MD, PhD, FESC a, Takayuki Okamura, MD, PhD a, Carlo di Mario, MD, PhD, FESC, FACC c, Gerrit-Anne van Es, MSc, PhD d, Stephan Windecker, MD, PhD, FESC b, Patrick W. Serruys, MD, PhD, FESC, FACC a,
a Erasmus Medical Centre, Thoraxcentre, Rotterdam, The Netherlands 
b Schweizerisches Herzzentrum, Inselspital, Bern, Switzerland 
c Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, London, United Kingdom 
d Cardialysis BV, Rotterdam, The Netherlands 

Reprint requests: Patrick W. Serruys, MD, PhD, FESC, FACC, Erasmus MC, Thoraxcenter, Ba583a, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.

Resumen

Background

Histologic experimental studies have reported incomplete neointimal healing in overlapping with respect to nonoverlapping segments in drug-eluting stents (DESs), but these observations have not been confirmed in human coronary arteries hitherto. On the contrary, angiographic and optical coherence tomography studies suggest that DES overlap elicits rather an exaggerated than an incomplete neointimal reaction.

Methods

Optical coherence tomography studies from 2 randomized trials including sirolimus-eluting, biolimus-eluting, everolimus-eluting, and zotarolimus-eluting stents were analyzed at 9- to 13-month follow-up. Coverage in overlapping segments was compared versus the corresponding nonoverlapping segments of the same stents, using statistical pooled analysis.

Results

Forty-two overlaps were found in 31 patients: 11 in sirolimus-eluting stents, 3 in biolimus-eluting stents, 17 in everolimus-eluting stents, and 11 in zotarolimus-eluting stents. The risk ratio of incomplete coverage was 2.35 (95% CI 1.86-2.98) in overlapping versus nonoverlapping segments. Thickness of coverage in overlaps was only 85% (95% CI 81%-90%) of the thickness in nonoverlaps. Significant heterogeneity of the effect was observed, especially pronounced in the comparison of thickness of coverage (I2 = 90.31).

Conclusions

The effect of overlapping DES on neointimal inhibition is markedly heterogeneous: on average, DES overlap is associated with more incomplete and thinner coverage, but in some cases, the overlap elicits an exaggerated neointimal reaction, thicker than in the corresponding nonoverlapping segments. These results might help to understand why overlapping DES is associated with worse clinical outcomes, both in terms of thrombotic phenomena and in terms of restenosis and revascularization.

El texto completo de este artículo está disponible en PDF.

Esquema


 Randomized controlled trial registration nos. NCT00389220 and NCT00617084NCT00389220NCT00617084.


© 2013  Mosby, Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 166 - N° 1

P. 83 - juillet 2013 Regresar al número
Artículo precedente Artículo precedente
  • Heart failure performance measures: Eligibility and implementation in the community
  • Cecilia Berardi, Alanna M. Chamberlain, Francesca Bursi, Margaret M. Redfield, Sheila M. McNallan, Susan A. Weston, Ruoxiang Jiang, Véronique L. Roger
| Artículo siguiente Artículo siguiente
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading
  • In-Suk Kim, Young-Hoon Jeong, Udaya S. Tantry, Yongwhi Park, Dong-Hyun Lee, Kevin P. Bliden, Jin-Sin Koh, Jeong Rang Park, Jae-Sik Jang, Seok-Jae Hwang, Eun-Ha Koh, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim, Paul A. Gurbel

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.